A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome

BACKGROUND: Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a primary immunodeficiency disorder caused by heterozygous gain-of-function CXCR4 mutations. Myelokathexis is a kind of neutropenia caused by neutrophil retention in bone marrow and in WHIM syndrome is associa...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, David H., Velez, Daniel, Cho, Elena, Cowen, Edward W., DiGiovanna, John J., Pastrana, Diana V., Buck, Christopher B., Calvo, Katherine R., Gardner, Pamela J., Rosenzweig, Sergio D., Stratton, Pamela, Merideth, Melissa A., Kim, H. Jeffrey, Brewer, Carmen, Katz, James D., Kuhns, Douglas B., Malech, Harry L., Follmann, Dean, Fay, Michael P., Murphy, Philip M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541188/
https://www.ncbi.nlm.nih.gov/pubmed/37561579
http://dx.doi.org/10.1172/JCI164918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541188/
https://www.ncbi.nlm.nih.gov/pubmed/37561579
http://dx.doi.org/10.1172/JCI164918

Ejemplares similares